Oral vinorelbine: a feasible and safe partner for radiotherapy in the treatment of locally advanced non-small cell lung cancer

Concurrent chemoradiotherapy (CCRT) using cisplatin-based doublets represents the standard of care for locally advanced non-small cell lung cancer (NSCLC), having shown good efficacy and activity in clinical trials. Locally advanced NSCLC occurs frequently in the elderly population, which is often e...

Full description

Saved in:
Bibliographic Details
Published in:OncoTargets and therapy 2016-01, Vol.9, p.2359-2364
Main Authors: Perri, Francesco, Lazzari, Grazia, Della Vittoria Scarpati, Giuseppina, Silvano, Giovanni
Format: Article
Language:English
Subjects:
Cancer therapies
Cell cycle
Chemoradiotherapy
Chemotherapy
Drug therapy
Feasibility studies
Lung cancer
Lung cancer, Non-small cell
Medical prognosis
Methods
Neutropenia
Non-small cell lung cancer
Non-small cell lung carcinoma
Patient outcomes
Radiation therapy
Radiotherapy
Review
Toxicity
Tumors
Vinorelbine
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Concurrent chemoradiotherapy (CCRT) using cisplatin-based doublets represents the standard of care for locally advanced non-small cell lung cancer (NSCLC), having shown good efficacy and activity in clinical trials. Locally advanced NSCLC occurs frequently in the elderly population, which is often excluded by platinum-based CCRT administration, due to severe associated toxicities. This limitation has been overcome using new-generation drugs such as gemcitabine, docetaxel, paclitaxel, and vinorelbine, which have shown not only to be efficacious but also to have a favorable toxicity spectrum, both in association with cisplatin and as single agents. Vinorelbine is a vinca alkaloid that binds to tubulin, thus inhibiting mitotic microtubule polymerization. Previous studies have clearly demonstrated that vinorelbine acts as a radiosensitizing agent when administered intravenously or orally. Moreover, oral administration of vinorelbine has shown a good clinical safety profile in both elderly and younger patients. A comprehensive review of the literature data regarding use of oral vinorelbine concurrently with radiotherapy in NSCLC was done. Single-agent oral vinorelbine may represent an effective therapy option for elderly patients with locally advanced lung cancer. This review has described the use of oral vinorelbine both as a monochemotherapy and in combination with cisplatin in the context of CCRT.
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S103645